Eur Rev Med Pharmacol Sci 2020; 24 (12): 6480-6481
DOI: 10.26355/eurrev_202006_21628

The complement inhibitors in COVID-19: future expectations

Y. Korotchaeva, N. Kozlovskaya, L. Bobrova, E. Kamyshova, K. Demyanova, S. Moiseev

Sechenov First Moscow State Medical University, Moscow, Russian Federation. kamyshova-es@yandex.ru

Free PDF Download

To cite this article

Y. Korotchaeva, N. Kozlovskaya, L. Bobrova, E. Kamyshova, K. Demyanova, S. Moiseev
The complement inhibitors in COVID-19: future expectations

Eur Rev Med Pharmacol Sci
Year: 2020
Vol. 24 - N. 12
Pages: 6480-6481
DOI: 10.26355/eurrev_202006_21628

Keywords Related articles:

  1. Management of atrial fibrillation in the Emergency Department: current approach and future expectations
  2. Impact of COVID-19 pandemic on otolaryngology, ophthalmology and dental clinical activity and future perspectives
  3. Imbalance between procoagulant factors and natural coagulation inhibitors contributes to hypercoagulability in the critically ill COVID-19 patient: clinical implications
  4. HIV/AIDS patient’s satisfactory and their expectations with pharmacy service at specialist antiretroviral therapy (ART) units
  5. Evaluation of complement system in children with Crimean-Congo hemorrhagic fever